Completed OBSERVATIONAL NCT06945146

Genomics Study in CML Patients With Ponatinib Treatment (CAP)

The Comprehensive Assessment of BCR-ABL1 Gene Expression and Genetic Variations by qRT-PCR and NGS Assays in Chronic Myeloid Leukemia Patients Who Are Treated With Ponatinib (CAP Study)

Sponsor: Dong-Wook Kim

Conditions Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Interventions Ponatinib

Updated 2 times since 2025 Last updated: Apr 18, 2025 Started: Sep 1, 2020 Primary completion: Aug 31, 2024 Completion: Sep 25, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06945146, this observational or N/A phase trial focuses on Chronic Myelogenous Leukemia, BCR-ABL1 Positive and remains completed. Sponsored by Dong-Wook Kim, it has been updated 2 times since 2020, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

2 versions recorded

Sep 2025 — Present [monthly]

Completed
May 2025 — Sep 2025 [monthly]

Completed

First recorded

Sep 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dong-Wook Kim
Takeda
Ulsan National Institute of Science and Technology

Data source: Eulji University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea